Cell Counting Market: Key Market Players & Growth Strategies Adopted by Them

The global cell counting market is projected to reach USD 12.32 billion by 2023 from USD 8.84 billion in 2018, at a CAGR of 6.8%. Factors such as growing incidence of diseases and disorders, development of enhanced solutions and improved image analysis, and growing use of high-throughput flow cytometry and automated hematology analyzers are driving the growth of this market. Emerging markets are expected to provide growth opportunities for players operating in the cell counting market in the coming years. However, the high cost of advanced cell counting systems and product recalls for instruments such as hematology analyzers are restraining the growth of this market to a certain extent.

Players in the global cell counting market, such as Danaher Corporation (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), Merck (Germany), Bio-Rad Laboratories (US), Agilent Technologies (US), BioTek Instruments (US), GE Healthcare (US), PerkinElmer (US), Tecan Group (Switzerland), Roche Diagnostics (Switzerland), and Sysmex Corporation (Japan) are focusing on increasing their presence in the high-growth markets through both organic as well as inorganic growth strategies of product launches, expansions, agreements, collaborations, and acquisitions.

To know the Insights download the pdf brochure

Danaher Corporation was the leading player in the cell counting market and accounted for the largest share in 2017. The company has a diversified product portfolio, which comprises of a wide range of instruments and consumables. Danaher offers a number of cell counters, flow cytometers, and hematology analyzers along with a wide range of consumables. Within the Danaher Business System (DBS) framework, the company is pursuing the expansion of its portfolio into new and attractive business areas. It significantly invests in R&D activities to add innovative technologies and products to its portfolio, which, in turn, helps it to strengthen its presence in the market. In 2018, the company launched the DxH 900 hematology analyzer, and in 2017, the company launched two new flow cytometry systems. With a strong portfolio of cell analysis instruments and incessant efforts to develop innovative products, the company is likely to maintain its strong position in this market in the coming years. The company further intends to strengthen its presence in the market by pursuing strategic business acquisitions. The company has alleviated its position in the global cell counting market by bringing the complementary portfolios of Leica Microsystems (Germany), Beckman Coulter (US), and Molecular Devices (US) under one brand, in the last five years. With a strong global presence and distribution network, with subsidiaries in more than 60 countries, Danaher has an edge over its competitors in this market.

Thermo Fisher was the second-largest market player in the cell counting market in 2017. The company offers various innovative flow cytometers, cell counters, microplate readers, and spectrophotometers, along with all consumables ranging from reagents, beads & microspheres, to stains and buffers. The company’s stronghold in the global cell counting market is largely attributed to its innovative product portfolio and strong relationships with its customers, owing to its strong sales and distribution network. It also leverages the advantage of three well-established brands—Thermo Scientific, Fisher Scientific, and Unity Lab Services. Additionally, the large number of production sites gives it a competitive advantage over other players in the cell counting market. The company further intends to strengthen its product portfolio by investing in R&D. The company’s extensive research and development activities enable it to increase its depth of capabilities in technologies, software, and services. Moreover, its significant investment in R&D enables it to provide innovative products in the market space, thus enabling it to maintain and improve its competitive position in the cell analysis market. In line with this, the company has launched its new spectrophotometer units in 2018. The company’s FDA and CE Mark-approved products have helped it to further enhance its presence in this market. Furthermore, Thermo Fisher expanded its presence in the US and South Korea in 2016 by opening new GMP facilities. Moreover, the company aims to strengthen its presence in selected geographies in the Asia Pacific region, undertaking various organic and inorganic growth strategies.